Fosun Pharma USA Inc.
Established in 2017 and headquartered in Princeton, New Jersey, Fosun Pharma USA Inc. (“Fosun USA”) is a wholly owned subsidiary of Fosun Pharma (Group) co., Ltd Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun HQ”) [Stock Code: 600196.SH, 02196.HK].
- Started as generics pharmaceutical company
- Developed into specialty generics and 505(b)(2) space
- Launched the Innovative Medicines Division in 2022 focusing on oncology
- Building pipeline with mid-to-late development stage (phase 2 and beyond) or commercial stage innovative products US market
* As of 8/5/24.
† Shanghai Fosun Pharmaceutical (Group) company website.
† Shanghai Fosun Pharmaceutical (Group) company website.
- Parent organization is Fosun Pharma Group
- ~$8 billion Market Cap*
- ~$6 billion revenues in 2023†
- ~30 years of a successful track record that includes partnerships with BioNTech and Intuitive Surgical
- Fosun Pharma Group has ownership of Fosun Pharma USA and partnership with Henlius
- Fosun Pharma USA has preferred access to Henlius for US development consideration
